‘ChatGPT for Doctors’ Mulls New Financing at $20 Billion Valuation

July 18, 2026 - 10:04

OpenEvidence, the artificial intelligence startup that markets its chatbot as a "ChatGPT for doctors," is considering a new round of financing that could value the company at roughly $20 billion. According to a person familiar with the discussions, the company has received offers from investors and is weighing a raise of about $200 million.

The startup specializes in helping physicians quickly find and verify medical information by using a large language model trained on clinical data. Unlike general-purpose chatbots, OpenEvidence's tool is designed to pull from peer-reviewed journals, drug databases, and treatment guidelines, aiming to reduce the time doctors spend sifting through search results.

The potential valuation marks a significant leap for the company, which has grown rapidly as hospitals and clinics look for ways to integrate AI into daily workflows. The new funding would likely fuel further product development and expansion into more healthcare systems.

The company is unlikely to finalize the round immediately, as it continues to evaluate terms. The talks remain private, and no formal agreement has been signed. OpenEvidence has not publicly commented on the reports. The interest from investors reflects a broader trend of venture capital flowing into AI-driven healthcare tools, despite a cautious regulatory environment.